Wo Wu Biological: the clinical trial application for the umbilical cord mesenchymal stem cell type II injection of the subsidiary has been accepted.

Iwu Biology announced that its indirectly controlled subsidiary Zhejiang Iwu Stem Cell Technology Co., Ltd. has received the "Acceptance Notice" issued by the National Medical Products Administration. The application for clinical trials of "Human Umbilical Cord Mesenchymal Stem Cell Type II Injection" submitted by Zhejiang Stem Cells has been officially accepted.